Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.
Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.
复制标题
DOI：
10.1007/s10555-012-9398-0
复制
发表时间：
2013-06
影响因子：
9.2
通讯作者：
Pierga, Jean-Yves
中科院分区：
文献类型：
--
作者：
Bidard, Francois-Clement;Fehm, Tanja;Ignatiadis, Michail;Smerage, Jeffrey B.;Alix-Panabieres, Catherine;Janni, Wolfgang;Messina, Carlo;Paoletti, Costanza;Mueller, Volkmar;Hayes, Daniel F.;Piccart, Martine;Pierga, Jean-Yves
2004年，据报道，在基线和治疗期间通过CellSearch®技术进行的循环肿瘤细胞（CTC）计数与转移性乳腺癌患者的预后相关。2008年，首次报道了通过该技术检测CTC对cM 0（i+）患者生存率影响的证据。这些发现得到了其他非干预性研究的证实，而CTC也作为肿瘤生物学的替代物进行了研究，主要用于HER 2表达/扩增。本报告的目的是介绍目前专门设计用于证明CTC计数/表征可改善乳腺癌患者管理的前瞻性大型干预性研究：STIC CTC METABREAST（法国）和内分泌治疗指数（美国）评估了M1患者中CTC指导的激素治疗与化疗决策; SWOG 0500（美国）和CirCe 01（法国）评估转移性患者治疗期间的CTC计数变化;侦探III（M1患者，德国）和Treat CTC（cM 0（i+）患者，欧洲癌症研究和治疗组织/乳腺癌国际组织）评估抗HER 2治疗在HER 2-基于CTC检测/表征选择的阴性乳腺癌患者。这些试验在不同的患者人群中具有不同的设计，但预计将成为CTC在乳腺癌患者常规管理中实施的关键试验。
In 2004, circulating tumor cells (CTC) enumeration by the CellSearch® technique at baseline and during treatment was reported to be associated with prognosis in metastatic breast cancer patients. In 2008, the first evidence of the impact of CTC detection by this technique on survival of cM0(i+) patients were reported. These findings were confirmed by other non-interventional studies, whereas CTC were also investigated as a surrogate for tumor biology, mainly for HER2 expression/amplification. The aim of this report is to present the current prospective large interventional studies that have been specifically designed to demonstrate that CTC enumeration/characterization may improve the management of breast cancer patients: STIC CTC METABREAST (France) and Endocrine Therapy Index (USA) assess the CTC-guided hormone therapy vs chemotherapy decision in M1 patients; SWOG0500 (USA) and CirCe01 (France) assess the CTC count changes during treatment in metastatic patients; DETECT III (M1 patients, Germany) and Treat CTC (cM0(i+) patients, European Organization for Research and Treatment of Cancer/Breast International Group) assess the use of anti-HER2 treatments in HER2-negative breast cancer patients selected on the basis of CTC detection/characterization. These trials have different designs in various patient populations but are expected to be the pivotal trials for CTC implementation in the routine management of breast cancer patients.
登录
查看更多内容
影响因子：
3.8
作者：
Giordano, Antonio;Giuliano, Mario;Reuben, James M.
通讯作者：
Reuben, James M.
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
DOI：
10.1186/bcr1783
发表时间：
2007
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Fehm T;Becker S;Duerr-Stoerzer S;Sotlar K;Mueller V;Wallwiener D;Lane N;Solomayer E;Uhr J
通讯作者：
Uhr J
影响因子：
45.3
作者：
Perez, Edith A.;Romond, Edward H.;Wolmark, Norman
通讯作者：
Wolmark, Norman
影响因子：
158.5
作者：
Cristofanilli, M;Budd, GT;Hayes, DF
通讯作者：
Hayes, DF